Heart BMJ

MARCH 26, 2025

Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. Among patients with myocardial infarction, a 1-SD increase in pulse pressure was associated with a 1.60-fold

Aortic valve 52

Aortic valve Myocardial Infarction Preserved Ejection Fraction Heart Failure 52

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. HFrEF is more commonly.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

Circulation: Heart Failure

NOVEMBER 25, 2024

Spironolactone improved outcomes in patients with severely symptomatic HF with reduced ejection fraction, and later, eplerenone expanded the benefits to patients with mildly symptomatic HF with reduced ejection fraction and myocardial infarction complicated by HF.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

DAIC

FEBRUARY 29, 2024

12:15 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population. per 100 patient-years).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] I think we live in a very exciting time right now for those who work in diabetes and cardiovascular disease.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiology Update

APRIL 9, 2024

EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. in the medical therapy group.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52